{"description":"All Documents","count":10000,"total_pages":50,"next_page_url":"https://www.federalregister.gov/api/v1/documents?format=json&page=3&search_after_cursor=WzE3OTE1MDQwMDAwMDAsIjIwMjYtMjA3NTEiXQ","previous_page_url":"https://www.federalregister.gov/api/v1/documents?format=json&page=1&search_after_cursor=WzE3OTE1MDQwMDAwMDAsIjIwMjYtMjA3NzEiXQ","results":[{"title":"Center For Scientific Review; Notice of Closed Meetings","type":"Notice","abstract":null,"document_number":"2026-20770","html_url":"https://www.federalregister.gov/documents/2026/10/09/2026-20770/center-for-scientific-review-notice-of-closed-meetings","pdf_url":"https://www.govinfo.gov/content/pkg/FR-2026-10-09/pdf/2026-20770.pdf","public_inspection_pdf_url":"https://public-inspection.federalregister.gov/2026-20770.pdf?1791463516","publication_date":"2026-10-09","agencies":[{"raw_name":"DEPARTMENT OF HEALTH AND HUMAN SERVICES","name":"Health and Human Services Department","id":221,"url":"https://www.federalregister.gov/agencies/health-and-human-services-department","json_url":"https://www.federalregister.gov/api/v1/agencies/221","parent_id":null,"slug":"health-and-human-services-department"},{"raw_name":"National Institutes of Health","name":"National Institutes of Health","id":353,"url":"https://www.federalregister.gov/agencies/national-institutes-of-health","json_url":"https://www.federalregister.gov/api/v1/agencies/353","parent_id":221,"slug":"national-institutes-of-health"}],"excerpts":null},{"title":"Issuance of Priority Review Voucher; Rare Pediatric Disease Product; ZANVASTRO (Zilganersen)","type":"Notice","abstract":"The Food and Drug Administration (FDA) is announcing the issuance of a priority review voucher to the sponsor of a rare pediatric disease product application. The Federal Food, Drug, and Cosmetic Act (FD&C Act) authorizes FDA to award priority review vouchers to sponsors of approved rare pediatric disease product applications that meet certain criteria. FDA is required to publish notice of the award of the priority review voucher. FDA has determined that ZANVASTRO (zilganersen), approved September 3, 2026, manufactured by Ionis Pharmaceuticals, Inc., meets the criteria for a priority review voucher.","document_number":"2026-20769","html_url":"https://www.federalregister.gov/documents/2026/10/09/2026-20769/issuance-of-priority-review-voucher-rare-pediatric-disease-product-zanvastro-zilganersen","pdf_url":"https://www.govinfo.gov/content/pkg/FR-2026-10-09/pdf/2026-20769.pdf","public_inspection_pdf_url":"https://public-inspection.federalregister.gov/2026-20769.pdf?1791463516","publication_date":"2026-10-09","agencies":[{"raw_name":"DEPARTMENT OF HEALTH AND HUMAN SERVICES","name":"Health and Human Services Department","id":221,"url":"https://www.federalregister.gov/agencies/health-and-human-services-department","json_url":"https://www.federalregister.gov/api/v1/agencies/221","parent_id":null,"slug":"health-and-human-services-department"},{"raw_name":"Food and Drug Administration","name":"Food and Drug Administration","id":199,"url":"https://www.federalregister.gov/agencies/food-and-drug-administration","json_url":"https://www.federalregister.gov/api/v1/agencies/199","parent_id":221,"slug":"food-and-drug-administration"}],"excerpts":"The Food and Drug Administration (FDA) is announcing the issuance of a priority review voucher to the sponsor of a rare pediatric disease product application. The Federal Food, Drug, and Cosmetic Act (FD&C Act) authorizes FDA to award priority review..."},{"title":"Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; Biologics License Applications, Procedures and Requirements","type":"Notice","abstract":"The Food and Drug Administration (FDA, Agency, or we) is announcing that a proposed collection of information has been submitted to the Office of Management and Budget (OMB) for review and clearance under the Paperwork Reduction Act of 1995.","document_number":"2026-20768","html_url":"https://www.federalregister.gov/documents/2026/10/09/2026-20768/agency-information-collection-activities-submission-for-office-of-management-and-budget-review","pdf_url":"https://www.govinfo.gov/content/pkg/FR-2026-10-09/pdf/2026-20768.pdf","public_inspection_pdf_url":"https://public-inspection.federalregister.gov/2026-20768.pdf?1791463515","publication_date":"2026-10-09","agencies":[{"raw_name":"DEPARTMENT OF HEALTH AND HUMAN SERVICES","name":"Health and Human Services Department","id":221,"url":"https://www.federalregister.gov/agencies/health-and-human-services-department","json_url":"https://www.federalregister.gov/api/v1/agencies/221","parent_id":null,"slug":"health-and-human-services-department"},{"raw_name":"Food and Drug Administration","name":"Food and Drug Administration","id":199,"url":"https://www.federalregister.gov/agencies/food-and-drug-administration","json_url":"https://www.federalregister.gov/api/v1/agencies/199","parent_id":221,"slug":"food-and-drug-administration"}],"excerpts":"The Food and Drug Administration (FDA, Agency, or we) is announcing that a proposed collection of information has been submitted to the Office of Management and Budget (OMB) for review and clearance under the Paperwork Reduction Act of 1995."},{"title":"Notice of Availability of the Proposed Notice of Sale for Gulf of America Outer Continental Shelf Oil and Gas One Big Beautiful Bill Act Lease Sale 4","type":"Notice","abstract":"The Bureau of Ocean Energy Management (BOEM) announces the availability of the Proposed Notice of Sale (NOS) for the Gulf of America (GOA) Outer Continental Shelf (OCS) Oil and Gas One Big Beautiful Bill Act (OBBBA) Lease Sale 4 (Lease Sale BBG4). BOEM is publishing this Notice pursuant to its regulatory authority under 30 CFR part 556. Pursuant to Section 19 of the OCS Lands Act, the Secretary of the Interior provides the Governors of affected States and the executive of any affected local government with the opportunity to review and comment on the Proposed NOS. The Proposed NOS describes the proposed size, timing, and location of the sale, including lease stipulations, terms and conditions, minimum bids, royalty rates, and rental rates which are required by Section 50102 of the OBBBA for this sale.","document_number":"2026-20767","html_url":"https://www.federalregister.gov/documents/2026/10/09/2026-20767/notice-of-availability-of-the-proposed-notice-of-sale-for-gulf-of-america-outer-continental-shelf","pdf_url":"https://www.govinfo.gov/content/pkg/FR-2026-10-09/pdf/2026-20767.pdf","public_inspection_pdf_url":"https://public-inspection.federalregister.gov/2026-20767.pdf?1791463515","publication_date":"2026-10-09","agencies":[{"raw_name":"DEPARTMENT OF THE INTERIOR","name":"Interior Department","id":253,"url":"https://www.federalregister.gov/agencies/interior-department","json_url":"https://www.federalregister.gov/api/v1/agencies/253","parent_id":null,"slug":"interior-department"},{"raw_name":"Bureau of Ocean Energy Management","name":"Ocean Energy Management Bureau","id":575,"url":"https://www.federalregister.gov/agencies/ocean-energy-management-bureau","json_url":"https://www.federalregister.gov/api/v1/agencies/575","parent_id":253,"slug":"ocean-energy-management-bureau"}],"excerpts":"The Bureau of Ocean Energy Management (BOEM) announces the availability of the Proposed Notice of Sale (NOS) for the Gulf of America (GOA) Outer Continental Shelf (OCS) Oil and Gas One Big Beautiful Bill Act (OBBBA) Lease Sale 4 (Lease Sale BBG4). BOEM..."},{"title":"Determination of Regulatory Review Period for Purposes of Patent Extension; MONOFERRIC","type":"Notice","abstract":"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for MONOFERRIC and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.","document_number":"2026-20766","html_url":"https://www.federalregister.gov/documents/2026/10/09/2026-20766/determination-of-regulatory-review-period-for-purposes-of-patent-extension-monoferric","pdf_url":"https://www.govinfo.gov/content/pkg/FR-2026-10-09/pdf/2026-20766.pdf","public_inspection_pdf_url":"https://public-inspection.federalregister.gov/2026-20766.pdf?1791463515","publication_date":"2026-10-09","agencies":[{"raw_name":"DEPARTMENT OF HEALTH AND HUMAN SERVICES","name":"Health and Human Services Department","id":221,"url":"https://www.federalregister.gov/agencies/health-and-human-services-department","json_url":"https://www.federalregister.gov/api/v1/agencies/221","parent_id":null,"slug":"health-and-human-services-department"},{"raw_name":"Food and Drug Administration","name":"Food and Drug Administration","id":199,"url":"https://www.federalregister.gov/agencies/food-and-drug-administration","json_url":"https://www.federalregister.gov/api/v1/agencies/199","parent_id":221,"slug":"food-and-drug-administration"}],"excerpts":"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for MONOFERRIC and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an..."},{"title":"Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; Expanded Access to Investigational Drugs for Treatment Use","type":"Notice","abstract":"The Food and Drug Administration (FDA, Agency, or we) is announcing that a proposed collection of information has been submitted to the Office of Management and Budget (OMB) for review and clearance under the Paperwork Reduction Act of 1995.","document_number":"2026-20765","html_url":"https://www.federalregister.gov/documents/2026/10/09/2026-20765/agency-information-collection-activities-submission-for-office-of-management-and-budget-review","pdf_url":"https://www.govinfo.gov/content/pkg/FR-2026-10-09/pdf/2026-20765.pdf","public_inspection_pdf_url":"https://public-inspection.federalregister.gov/2026-20765.pdf?1791463515","publication_date":"2026-10-09","agencies":[{"raw_name":"DEPARTMENT OF HEALTH AND HUMAN SERVICES","name":"Health and Human Services Department","id":221,"url":"https://www.federalregister.gov/agencies/health-and-human-services-department","json_url":"https://www.federalregister.gov/api/v1/agencies/221","parent_id":null,"slug":"health-and-human-services-department"},{"raw_name":"Food and Drug Administration","name":"Food and Drug Administration","id":199,"url":"https://www.federalregister.gov/agencies/food-and-drug-administration","json_url":"https://www.federalregister.gov/api/v1/agencies/199","parent_id":221,"slug":"food-and-drug-administration"}],"excerpts":"The Food and Drug Administration (FDA, Agency, or we) is announcing that a proposed collection of information has been submitted to the Office of Management and Budget (OMB) for review and clearance under the Paperwork Reduction Act of 1995."},{"title":"Determination That LASIX (Furosemide) Oral Solution, 10 Milligrams/Milliliter, Was Not Withdrawn From Sale for Reasons of Safety or Effectiveness","type":"Notice","abstract":"The Food and Drug Administration (FDA, Agency, or we) has determined that LASIX (furosemide) oral solution, 10 milligrams (mg)/ milliliter (mL), was not withdrawn from sale for reasons of safety or effectiveness. This determination means that FDA will not begin procedures to withdraw approval of abbreviated new drug applications (ANDAs) that refer to this drug product, and it will allow FDA to continue to approve ANDAs that refer to the product as long as they meet relevant legal and regulatory requirements.","document_number":"2026-20764","html_url":"https://www.federalregister.gov/documents/2026/10/09/2026-20764/determination-that-lasix-furosemide-oral-solution-10-milligramsmilliliter-was-not-withdrawn-from","pdf_url":"https://www.govinfo.gov/content/pkg/FR-2026-10-09/pdf/2026-20764.pdf","public_inspection_pdf_url":"https://public-inspection.federalregister.gov/2026-20764.pdf?1791463515","publication_date":"2026-10-09","agencies":[{"raw_name":"DEPARTMENT OF HEALTH AND HUMAN SERVICES","name":"Health and Human Services Department","id":221,"url":"https://www.federalregister.gov/agencies/health-and-human-services-department","json_url":"https://www.federalregister.gov/api/v1/agencies/221","parent_id":null,"slug":"health-and-human-services-department"},{"raw_name":"Food and Drug Administration","name":"Food and Drug Administration","id":199,"url":"https://www.federalregister.gov/agencies/food-and-drug-administration","json_url":"https://www.federalregister.gov/api/v1/agencies/199","parent_id":221,"slug":"food-and-drug-administration"}],"excerpts":"The Food and Drug Administration (FDA, Agency, or we) has determined that LASIX (furosemide) oral solution, 10 milligrams (mg)/ milliliter (mL), was not withdrawn from sale for reasons of safety or effectiveness. This determination means that FDA will..."},{"title":"National Environmental Policy Act Implementing Procedures: Wintertime Oil and Gas Exploration in the National Petroleum Reserve in Alaska Categorical Exclusion","type":"Notice","abstract":"This notice announces a revision to the Department of the Interior (Department)'s National Environmental Policy Act (NEPA) procedures adding a new categorical exclusion (CE) for National Petroleum Reserve in Alaska (NPR-A) wintertime oil and gas exploration activities to the DOI Handbook of NEPA Implementing Procedures, Appendix 2: Bureau Categorical Exclusions.","document_number":"2026-20763","html_url":"https://www.federalregister.gov/documents/2026/10/09/2026-20763/national-environmental-policy-act-implementing-procedures-wintertime-oil-and-gas-exploration-in-the","pdf_url":"https://www.govinfo.gov/content/pkg/FR-2026-10-09/pdf/2026-20763.pdf","public_inspection_pdf_url":"https://public-inspection.federalregister.gov/2026-20763.pdf?1791463515","publication_date":"2026-10-09","agencies":[{"raw_name":"DEPARTMENT OF THE INTERIOR","name":"Interior Department","id":253,"url":"https://www.federalregister.gov/agencies/interior-department","json_url":"https://www.federalregister.gov/api/v1/agencies/253","parent_id":null,"slug":"interior-department"},{"raw_name":"Office of the Secretary"}],"excerpts":"This notice announces a revision to the Department of the Interior (Department)'s National Environmental Policy Act (NEPA) procedures adding a new categorical exclusion (CE) for National Petroleum Reserve in Alaska (NPR-A) wintertime oil and gas..."},{"title":"Par Health USA LLC, U.S. Agent for PH Health Limited, et al.; Withdrawal of Approval of 37 Abbreviated New Drug Applications","type":"Notice","abstract":"The Food and Drug Administration (FDA or Agency) is withdrawing approval of 37 abbreviated new drug applications (ANDAs) from multiple applicants. The applicants notified the Agency in writing that the drug products were no longer marketed and requested that the approval of the applications be withdrawn.","document_number":"2026-20762","html_url":"https://www.federalregister.gov/documents/2026/10/09/2026-20762/par-health-usa-llc-us-agent-for-ph-health-limited-et-al-withdrawal-of-approval-of-37-abbreviated-new","pdf_url":"https://www.govinfo.gov/content/pkg/FR-2026-10-09/pdf/2026-20762.pdf","public_inspection_pdf_url":"https://public-inspection.federalregister.gov/2026-20762.pdf?1791463515","publication_date":"2026-10-09","agencies":[{"raw_name":"DEPARTMENT OF HEALTH AND HUMAN SERVICES","name":"Health and Human Services Department","id":221,"url":"https://www.federalregister.gov/agencies/health-and-human-services-department","json_url":"https://www.federalregister.gov/api/v1/agencies/221","parent_id":null,"slug":"health-and-human-services-department"},{"raw_name":"Food and Drug Administration","name":"Food and Drug Administration","id":199,"url":"https://www.federalregister.gov/agencies/food-and-drug-administration","json_url":"https://www.federalregister.gov/api/v1/agencies/199","parent_id":221,"slug":"food-and-drug-administration"}],"excerpts":"The Food and Drug Administration (FDA or Agency) is withdrawing approval of 37 abbreviated new drug applications (ANDAs) from multiple applicants. The applicants notified the Agency in writing that the drug products were no longer marketed and..."},{"title":"Request for Comments on the Renewal of a Previously Approved Information Collection: War Risk Insurance, Applications, and Related Information","type":"Notice","abstract":"MARAD invites public comments on its intention to request Office of Management and Budget (OMB) approval to renew an information collection in accordance with the Paperwork Reduction Act of 1995. The proposed collection OMB 2133- 0011 (War Risk Insurance, Applications, and Related Information) is used to obtain war risk insurance from the U.S. Government, when such insurance is unavailable on reasonable terms from the commercial market. The program is mutually beneficial to the U.S. and the ship owner, in that it assures continued flow of essential U.S. trade and provides protection for the ship owner from loss by risks of war. MARAD is required to publish this notice in the Federal Register to obtain comments from the public and affected agencies.","document_number":"2026-20761","html_url":"https://www.federalregister.gov/documents/2026/10/09/2026-20761/request-for-comments-on-the-renewal-of-a-previously-approved-information-collection-war-risk","pdf_url":"https://www.govinfo.gov/content/pkg/FR-2026-10-09/pdf/2026-20761.pdf","public_inspection_pdf_url":"https://public-inspection.federalregister.gov/2026-20761.pdf?1791463515","publication_date":"2026-10-09","agencies":[{"raw_name":"DEPARTMENT OF TRANSPORTATION","name":"Transportation Department","id":492,"url":"https://www.federalregister.gov/agencies/transportation-department","json_url":"https://www.federalregister.gov/api/v1/agencies/492","parent_id":null,"slug":"transportation-department"},{"raw_name":"Maritime Administration","name":"Maritime Administration","id":282,"url":"https://www.federalregister.gov/agencies/maritime-administration","json_url":"https://www.federalregister.gov/api/v1/agencies/282","parent_id":492,"slug":"maritime-administration"}],"excerpts":"MARAD invites public comments on its intention to request Office of Management and Budget (OMB) approval to renew an information collection in accordance with the Paperwork Reduction Act of 1995. The proposed collection OMB 2133- 0011 (War Risk..."},{"title":"Request for Comments on the Renewal of a Previously Approved Information Collection: Application and Reporting Elements for Participation in the Tanker Security Program","type":"Notice","abstract":"MARAD invites public comments on its intention to request Office of Management and Budget (OMB) approval to renew an information collection in accordance with the Paperwork Reduction Act of 1995. The proposed collection OMB 2133-0554 (Application and Reporting Elements for Participation in the Tanker Security Program) is used to evaluate the eligibility of applicants for participation in the Tanker Security Program (TSP). Since the last renewal, the application form for this collection is being updated to include minor clerical amendments regarding the authorizing statute and procedures for electronic submission. MARAD is required to publish this notice in the Federal Register to obtain comments from the public and affected agencies.","document_number":"2026-20760","html_url":"https://www.federalregister.gov/documents/2026/10/09/2026-20760/request-for-comments-on-the-renewal-of-a-previously-approved-information-collection-application-and","pdf_url":"https://www.govinfo.gov/content/pkg/FR-2026-10-09/pdf/2026-20760.pdf","public_inspection_pdf_url":"https://public-inspection.federalregister.gov/2026-20760.pdf?1791463514","publication_date":"2026-10-09","agencies":[{"raw_name":"DEPARTMENT OF TRANSPORTATION","name":"Transportation Department","id":492,"url":"https://www.federalregister.gov/agencies/transportation-department","json_url":"https://www.federalregister.gov/api/v1/agencies/492","parent_id":null,"slug":"transportation-department"},{"raw_name":"Maritime Administration","name":"Maritime Administration","id":282,"url":"https://www.federalregister.gov/agencies/maritime-administration","json_url":"https://www.federalregister.gov/api/v1/agencies/282","parent_id":492,"slug":"maritime-administration"}],"excerpts":"MARAD invites public comments on its intention to request Office of Management and Budget (OMB) approval to renew an information collection in accordance with the Paperwork Reduction Act of 1995. The proposed collection OMB 2133-0554 (Application and..."},{"title":"Sunshine Act Meetings","type":"Notice","abstract":null,"document_number":"2026-20759","html_url":"https://www.federalregister.gov/documents/2026/10/09/2026-20759/sunshine-act-meetings","pdf_url":"https://www.govinfo.gov/content/pkg/FR-2026-10-09/pdf/2026-20759.pdf","public_inspection_pdf_url":"https://public-inspection.federalregister.gov/2026-20759.pdf?1791404112","publication_date":"2026-10-09","agencies":[{"raw_name":"Unified Carrier Registration Plan","name":"Unified Carrier Registration Plan","id":601,"url":"https://www.federalregister.gov/agencies/unified-carrier-registration-plan","json_url":"https://www.federalregister.gov/api/v1/agencies/601","parent_id":null,"slug":"unified-carrier-registration-plan"}],"excerpts":null},{"title":"Amneal Pharmaceuticals of New York, LLC; Withdrawal of Approval of Abbreviated New Drug Application for Celecoxib Capsules, 50 Milligrams, 100 Milligrams, 200 Milligrams, and 400 Milligrams","type":"Notice","abstract":"The Food and Drug Administration (FDA or Agency) is withdrawing approval of abbreviated new drug application (ANDA) 208833 for Celecoxib capsules, 50 milligrams (mg), 100 mg, 200 mg, and 400 mg, held by Amneal Pharmaceuticals of New York, LLC, 50 Horseblock Rd., Brookhaven, NY 11719 (Amneal). Amneal requested withdrawal of approval of this application and has waived its opportunity for a hearing.","document_number":"2026-20758","html_url":"https://www.federalregister.gov/documents/2026/10/09/2026-20758/amneal-pharmaceuticals-of-new-york-llc-withdrawal-of-approval-of-abbreviated-new-drug-application","pdf_url":"https://www.govinfo.gov/content/pkg/FR-2026-10-09/pdf/2026-20758.pdf","public_inspection_pdf_url":"https://public-inspection.federalregister.gov/2026-20758.pdf?1791463514","publication_date":"2026-10-09","agencies":[{"raw_name":"DEPARTMENT OF HEALTH AND HUMAN SERVICES","name":"Health and Human Services Department","id":221,"url":"https://www.federalregister.gov/agencies/health-and-human-services-department","json_url":"https://www.federalregister.gov/api/v1/agencies/221","parent_id":null,"slug":"health-and-human-services-department"},{"raw_name":"Food and Drug Administration","name":"Food and Drug Administration","id":199,"url":"https://www.federalregister.gov/agencies/food-and-drug-administration","json_url":"https://www.federalregister.gov/api/v1/agencies/199","parent_id":221,"slug":"food-and-drug-administration"}],"excerpts":"The Food and Drug Administration (FDA or Agency) is withdrawing approval of abbreviated new drug application (ANDA) 208833 for Celecoxib capsules, 50 milligrams (mg), 100 mg, 200 mg, and 400 mg, held by Amneal Pharmaceuticals of New York, LLC, 50..."},{"title":"Schedules of Controlled Substances; Removal of Exemption Status for Inactive Butalbital Products","type":"Rule","abstract":"The Drug Enforcement Administration (DEA) is revoking the exempted status for certain nonnarcotic prescription products that are currently on DEA's Table of Exempted Prescription Products, but whose National Drug Codes (NDC) are inactive because they are no longer available and/or the company that applied for the exemption no longer exists. These products will be removed from DEA's Table of Exempted Prescription Products and will no longer be considered exempt prescription products under the Controlled Substances Act. This action does not impact exempted prescription products with active NDC numbers.","document_number":"2026-20757","html_url":"https://www.federalregister.gov/documents/2026/10/09/2026-20757/schedules-of-controlled-substances-removal-of-exemption-status-for-inactive-butalbital-products","pdf_url":"https://www.govinfo.gov/content/pkg/FR-2026-10-09/pdf/2026-20757.pdf","public_inspection_pdf_url":"https://public-inspection.federalregister.gov/2026-20757.pdf?1791463514","publication_date":"2026-10-09","agencies":[{"raw_name":"DEPARTMENT OF JUSTICE","name":"Justice Department","id":268,"url":"https://www.federalregister.gov/agencies/justice-department","json_url":"https://www.federalregister.gov/api/v1/agencies/268","parent_id":null,"slug":"justice-department"},{"raw_name":"Drug Enforcement Administration","name":"Drug Enforcement Administration","id":116,"url":"https://www.federalregister.gov/agencies/drug-enforcement-administration","json_url":"https://www.federalregister.gov/api/v1/agencies/116","parent_id":268,"slug":"drug-enforcement-administration"}],"excerpts":"The Drug Enforcement Administration (DEA) is revoking the exempted status for certain nonnarcotic prescription products that are currently on DEA's Table of Exempted Prescription Products, but whose National Drug Codes (NDC) are inactive because they..."},{"title":"Sunshine Act Meetings","type":"Notice","abstract":null,"document_number":"2026-20756","html_url":"https://www.federalregister.gov/documents/2026/10/09/2026-20756/sunshine-act-meetings","pdf_url":"https://www.govinfo.gov/content/pkg/FR-2026-10-09/pdf/2026-20756.pdf","public_inspection_pdf_url":"https://public-inspection.federalregister.gov/2026-20756.pdf?1791404112","publication_date":"2026-10-09","agencies":[{"raw_name":"Unified Carrier Registration Plan","name":"Unified Carrier Registration Plan","id":601,"url":"https://www.federalregister.gov/agencies/unified-carrier-registration-plan","json_url":"https://www.federalregister.gov/api/v1/agencies/601","parent_id":null,"slug":"unified-carrier-registration-plan"}],"excerpts":null},{"title":"Sunshine Act Meetings","type":"Notice","abstract":null,"document_number":"2026-20755","html_url":"https://www.federalregister.gov/documents/2026/10/09/2026-20755/sunshine-act-meetings","pdf_url":"https://www.govinfo.gov/content/pkg/FR-2026-10-09/pdf/2026-20755.pdf","public_inspection_pdf_url":"https://public-inspection.federalregister.gov/2026-20755.pdf?1791404112","publication_date":"2026-10-09","agencies":[{"raw_name":"NUCLEAR REGULATORY COMMISSION","name":"Nuclear Regulatory Commission","id":383,"url":"https://www.federalregister.gov/agencies/nuclear-regulatory-commission","json_url":"https://www.federalregister.gov/api/v1/agencies/383","parent_id":null,"slug":"nuclear-regulatory-commission"}],"excerpts":null},{"title":"Agency Information Collection Activities; Comment Request; Integrated Postsecondary Education Data System (IPEDS) 2026-27 Through 2028-29","type":"Notice","abstract":"In accordance with the Paperwork Reduction Act (PRA) of 1995, the Department is proposing a revision of a currently approved information collection request (ICR).","document_number":"2026-20754","html_url":"https://www.federalregister.gov/documents/2026/10/09/2026-20754/agency-information-collection-activities-comment-request-integrated-postsecondary-education-data","pdf_url":"https://www.govinfo.gov/content/pkg/FR-2026-10-09/pdf/2026-20754.pdf","public_inspection_pdf_url":"https://public-inspection.federalregister.gov/2026-20754.pdf?1791463514","publication_date":"2026-10-09","agencies":[{"raw_name":"DEPARTMENT OF EDUCATION","name":"Education Department","id":126,"url":"https://www.federalregister.gov/agencies/education-department","json_url":"https://www.federalregister.gov/api/v1/agencies/126","parent_id":null,"slug":"education-department"}],"excerpts":"In accordance with the Paperwork Reduction Act (PRA) of 1995, the Department is proposing a revision of a currently approved information collection request (ICR)."},{"title":"Senior Executive Service Performance Review Board Membership","type":"Notice","abstract":null,"document_number":"2026-20753","html_url":"https://www.federalregister.gov/documents/2026/10/09/2026-20753/senior-executive-service-performance-review-board-membership","pdf_url":"https://www.govinfo.gov/content/pkg/FR-2026-10-09/pdf/2026-20753.pdf","public_inspection_pdf_url":"https://public-inspection.federalregister.gov/2026-20753.pdf?1791463514","publication_date":"2026-10-09","agencies":[{"raw_name":"Council of the Inspectors General on Integrity and Efficiency","name":"Council of the Inspectors General on Integrity and Efficiency","id":578,"url":"https://www.federalregister.gov/agencies/council-of-the-inspectors-general-on-integrity-and-efficiency","json_url":"https://www.federalregister.gov/api/v1/agencies/578","parent_id":null,"slug":"council-of-the-inspectors-general-on-integrity-and-efficiency"}],"excerpts":null},{"title":"Certain Hydrodermabrasion Systems and Components Thereof; Notice of Vacatur of the Commission's Final Determination and Mootness of the Investigation by the Federal Circuit Due to Patent Expiration","type":"Notice","abstract":"Notice is hereby given that the U.S. International Trade Commission's (\"Commission\") final determination in the above- captioned investigation has been vacated by the U.S. Court of Appeals for the Federal Circuit (\"Federal Circuit\") and the investigation is terminated as moot as ordered by the Federal Circuit. The investigation was previously terminated on March 23, 2026.","document_number":"2026-20752","html_url":"https://www.federalregister.gov/documents/2026/10/09/2026-20752/certain-hydrodermabrasion-systems-and-components-thereof-notice-of-vacatur-of-the-commissions-final","pdf_url":"https://www.govinfo.gov/content/pkg/FR-2026-10-09/pdf/2026-20752.pdf","public_inspection_pdf_url":"https://public-inspection.federalregister.gov/2026-20752.pdf?1791463514","publication_date":"2026-10-09","agencies":[{"raw_name":"INTERNATIONAL TRADE COMMISSION","name":"International Trade Commission","id":262,"url":"https://www.federalregister.gov/agencies/international-trade-commission","json_url":"https://www.federalregister.gov/api/v1/agencies/262","parent_id":null,"slug":"international-trade-commission"}],"excerpts":"Notice is hereby given that the U.S. International Trade Commission's (\"Commission\") final determination in the above- captioned investigation has been vacated by the U.S. Court of Appeals for the Federal Circuit (\"Federal Circuit\") and the..."},{"title":"Alexandra R. Lovec, A.P.R.N.; Decision and Order","type":"Notice","abstract":null,"document_number":"2026-20751","html_url":"https://www.federalregister.gov/documents/2026/10/09/2026-20751/alexandra-r-lovec-aprn-decision-and-order","pdf_url":"https://www.govinfo.gov/content/pkg/FR-2026-10-09/pdf/2026-20751.pdf","public_inspection_pdf_url":"https://public-inspection.federalregister.gov/2026-20751.pdf?1791463514","publication_date":"2026-10-09","agencies":[{"raw_name":"DEPARTMENT OF JUSTICE","name":"Justice Department","id":268,"url":"https://www.federalregister.gov/agencies/justice-department","json_url":"https://www.federalregister.gov/api/v1/agencies/268","parent_id":null,"slug":"justice-department"},{"raw_name":"Drug Enforcement Administration","name":"Drug Enforcement Administration","id":116,"url":"https://www.federalregister.gov/agencies/drug-enforcement-administration","json_url":"https://www.federalregister.gov/api/v1/agencies/116","parent_id":268,"slug":"drug-enforcement-administration"}],"excerpts":null}]}